Arquebio Bioprocessing

  • arquebio@arquebio.com
  • c/ Àlaba 51, 3r 7ª
Contact

Maresin

Home

Maresin

Executive Summary

  • ARQUEBIO develops bio-synthetic processes.
  • There is an endogenous compound that mammalian immune systems can synthesize in an inflammatory state.
  • Chemical synthesis can be achieved, but it takes 10 steps and produces only a 7% yield.
  • The price is astronomical (e.g., 5 M € / g).
  • Potential therapeutic properties of the compound include Amyotrophic lateral sclerosis, Multipls Sclerosis, Rheumatoid Arthritis, Asthma, Covid-19 and other acute respiratory insufficiency syndromes (mortality).
  • It is like a treasure, seen from afar off but too difficult to reach.
  • ARQUEBIO intends to solve the problem.
  • Since 2018, ARQUEBIO has been working in a bio-synthetic process to produce MARESIN, and success in in sight.
  • A relatively cheap and accessible source of MARESIN will drastically accelerate research in both pre-clinical and clinical settings.

Elevator pitch

ARQUEBIO has believed in what no one else has and now is close, very close, to achieve this milestone, which has the potential to become a breakthrough for Medical Sciences.

Maresin is a known natural and endogenous anti-inflammatory agent with known therapeutic activity against Asthma, Acute respiratory insufficiency syndromes, Amyotrophic lateral sclerosis, Multiple Sclerosis, Rheumatoid Arthritis, potentially diabetes and some cancers. What is impeding its adoption as a pharmaceutical drug is its availability at a reasonable cost.

Partnerships

Arquebio SL is open to partner with investors who realize the unique potential of our work. Please contact us at arquebio@arquebio.com to receive more details about this life sciences game changer.

Market Size

Asthma

combined worldwide sales of Montelukast (Singulair®), Salbutamol (Ventolin®), Benralizumab (Fasernra®), Mepolizumab (Nucala®) , Fluticasone&Vilanterol (Breo Ellipta®) : > € 15.000 million.

Rheumatoid Arthritis

combined worldwide sales of Methotrexate (Trexall® & Otrexup®), Leflunomide (Arava®) and Hydroxychloroquine (Plaquenil®) > € 1.700 million.

Multiple Sclerosis

combined worldwide sales of Fingolimod (Gilenya®) and Dimethyl Fumarate (Tecfidera®) > € 8.500 million.

COVID19

difficult to estimate atm.

Other studies and bibliography

bring evidences of its activity in some diabetes / cancer diseases.

Protection of know-how

All the generated know-how and IP is protected through notarial documents and industrial secrecy. Patenting will be started once Bio-synthesis of Maresin is solved. According to investor policy/strategy.
Meet

OUR TEAM

Jaume Mir

PhD Biochemistry.
36 years experience in chemical, pharma and biotech industries.
Founder and CEO of ARQUEBIO.

Manel Gil

Economy and Finance.
30 yrs CFO experience.
CFO of ARQUEBIO.

Jordi Bosch

PhD Organic Chemistry.
28 yrs experience in Generic API industry.
Founder of SCIRA Consulting.
BD of ARQUEBIO.

Who backs our Strategy

We have started an international round of contacts with renowned names in the relevant therapeutic fields to present our status of development.